Advertisement
Australia markets close in 57 minutes
  • ALL ORDS

    7,796.10
    -102.80 (-1.30%)
     
  • ASX 200

    7,544.90
    -97.20 (-1.27%)
     
  • AUD/USD

    0.6400
    -0.0025 (-0.39%)
     
  • OIL

    84.44
    +1.71 (+2.07%)
     
  • GOLD

    2,398.00
    0.00 (0.00%)
     
  • Bitcoin AUD

    97,169.43
    +883.90 (+0.92%)
     
  • CMC Crypto 200

    1,288.74
    +403.20 (+44.39%)
     
  • AUD/EUR

    0.6016
    -0.0015 (-0.24%)
     
  • AUD/NZD

    1.0881
    +0.0007 (+0.06%)
     
  • NZX 50

    11,756.31
    -79.73 (-0.67%)
     
  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     
  • FTSE

    7,877.05
    +29.06 (+0.37%)
     
  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     
  • DAX

    17,837.40
    +67.38 (+0.38%)
     
  • Hang Seng

    16,181.15
    -204.72 (-1.25%)
     
  • NIKKEI 225

    37,037.58
    -1,042.12 (-2.74%)
     

Could Roche Put a Crinkle in Biogen's Alzheimer's Drug Launch?

Roche (OTC: RHHBY) is considering a launch of its Alzheimer's disease drug, gantenerumab, at a price that could undercut competition from Biogen's (NASDAQ: BIIB) Aduhelm. In this Motley Fool Live video recorded on Nov. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss reasons why Biogen investors should be concerned if Roche's drug gains FDA approval.